We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,328 hedge funds and large institutions have $61.1B invested in Bristol-Myers Squibb in 2014 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 461 increasing their positions, 567 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 60

16% more call options, than puts

Call options by funds: $856M | Put options by funds: $741M

1% more funds holding

Funds holding: 1,3131,328 (+15)

0.51% more ownership

Funds ownership: 70.46%70.98% (+0.51%)

1% less capital invested

Capital invested by funds: $61.7B → $61.1B (-$592M)

12% less funds holding in top 10

Funds holding in top 10: 6557 (-8)

19% less repeat investments, than reductions

Existing positions increased: 461 | Existing positions reduced: 567

Holders
1,328
Holders Change
+15
Holders Change %
+1.14%
% of All Funds
38.35%
Holding in Top 10
57
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-12.31%
% of All Funds
1.65%
New
90
Increased
461
Reduced
567
Closed
60
Calls
$856M
Puts
$741M
Net Calls
+$116M
Net Calls Change
+$210M
Name Holding Trade Value Shares
Change
Change in
Stake
PRC
301
Platte River Capital
Colorado
$10.2M -$2.73M -51,350 -21%
CIM
302
Contravisory Investment Management
Massachusetts
$9.95M +$10.2M +191,502 New
JWBC
303
J.W. Burns & Co
New York
$9.86M -$145K -2,721 -1%
WA
304
WealthTrust Axiom
Pennsylvania
$9.85M -$2.85M -53,583 -22%
PSUF
305
People's United Financial
Connecticut
$9.72M +$420K +7,902 +4%
RSCM
306
Rock Springs Capital Management
Maryland
$9.64M +$266K +5,000 +3%
B
307
BP
United Kingdom
$9.61M +$1.33M +25,000 +16%
TI
308
Turner Investments
Pennsylvania
$9.46M -$3.7M -69,552 -28%
BG
309
Bahl & Gaynor
Ohio
$9.44M -$38.1M -716,277 -80%
VFAM
310
Valley Forge Asset Management
Pennsylvania
$9.35M -$10.9M -204,788 -53%
NPF
311
Norris Perne & French
Michigan
$9.31M +$252K +4,742 +3%
MOACM
312
Mutual of America Capital Management
New York
$9.24M +$206K +3,866 +2%
AHB
313
Abner Herrman & Brock
New Jersey
$9.21M +$17.3K +325 +0.2%
CA
314
CapWealth Advisors
Tennessee
$9.12M +$6.65K +125 +0.1%
SMDAM
315
Sumitomo Mitsui DS Asset Management
Japan
$9.08M -$596K -11,208 -6%
IGIM
316
I.G. Investment Management
Manitoba, Canada
$8.98M +$4.09M +76,870 +80%
AAM
317
Aberdeen Asset Management
United Kingdom
$8.97M -$37.2K -700 -0.4%
FFSOTS
318
Fiduciary Financial Services of The Southwest
Texas
$8.89M +$82.2K +1,545 +0.9%
DADC
319
D.A. Davidson & Co
Montana
$8.88M -$1.74M -32,607 -16%
WSFS
320
Wilmington Savings Fund Society
Delaware
$8.84M -$59.5K -1,119 -0.7%
GKIM
321
GW&K Investment Management
Massachusetts
$8.72M -$6.23M -117,097 -41%
Alyeska Investment Group
322
Alyeska Investment Group
Illinois
$8.69M -$5.99M -112,638 -40%
GL
323
GLG LLC
New York
$8.64M +$8.86M +166,413 New
QI
324
Qualcomm Inc
California
$8.64M
TU
325
TDAM USA
Ontario, Canada
$8.6M -$425K -7,979 -5%

BMY Hedge Fund Activity: Q1 2014 in Review

1,328 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2014, worth a combined $61.1B — down 0.96% from $61.7B a quarter earlier.

Buyers outnumbered sellers: 90 funds opened new BMY positions and 60 closed out — a net gain of 30 holders — while 461 added to existing stakes and 567 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.5B. The largest seller was Capital World Investors, cutting an estimated $1.5B.

  • 1,328 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2014, up from 1,313 in Q4 2013.
  • Funds reported $61.1B of Bristol-Myers Squibb stock for Q1 2014, down 0.96% quarter-over-quarter.
  • 90 funds opened new Bristol-Myers Squibb positions in Q1 2014 and 60 closed out, a net change of +30 holders.
  • The largest Bristol-Myers Squibb buyer in Q1 2014 was Fidelity Investments, an estimated $1.5B added.
  • The largest Bristol-Myers Squibb seller in Q1 2014 was Capital World Investors, an estimated $1.5B sold.

Based on aggregated 13F filings for Q1 2014.